SG11202102163SA - Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery - Google Patents
Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid deliveryInfo
- Publication number
- SG11202102163SA SG11202102163SA SG11202102163SA SG11202102163SA SG11202102163SA SG 11202102163S A SG11202102163S A SG 11202102163SA SG 11202102163S A SG11202102163S A SG 11202102163SA SG 11202102163S A SG11202102163S A SG 11202102163SA SG 11202102163S A SG11202102163S A SG 11202102163SA
- Authority
- SG
- Singapore
- Prior art keywords
- nucleic acid
- lipid nanoparticle
- cationic peptide
- peptide compounds
- acid delivery
- Prior art date
Links
- 125000002091 cationic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738717P | 2018-09-28 | 2018-09-28 | |
| US201962885036P | 2019-08-09 | 2019-08-09 | |
| PCT/US2019/053661 WO2020069445A1 (en) | 2018-09-28 | 2019-09-27 | Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102163SA true SG11202102163SA (en) | 2021-04-29 |
Family
ID=69952323
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102164PA SG11202102164PA (en) | 2018-09-28 | 2019-09-27 | Tertiary amino lipidated cationic peptides for nucleic acid delivery |
| SG11202102163SA SG11202102163SA (en) | 2018-09-28 | 2019-09-27 | Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102164PA SG11202102164PA (en) | 2018-09-28 | 2019-09-27 | Tertiary amino lipidated cationic peptides for nucleic acid delivery |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20210322575A1 (en) |
| EP (2) | EP3856757A4 (en) |
| JP (2) | JP7418419B2 (en) |
| KR (2) | KR20210068093A (en) |
| CN (2) | CN112789031B (en) |
| AU (2) | AU2019351268A1 (en) |
| BR (2) | BR112021005815A2 (en) |
| CA (2) | CA3110914A1 (en) |
| IL (2) | IL281135B1 (en) |
| MX (2) | MX2021003420A (en) |
| SG (2) | SG11202102164PA (en) |
| WO (2) | WO2020069442A1 (en) |
| ZA (2) | ZA202101376B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020069442A1 (en) * | 2018-09-28 | 2020-04-02 | Nutcracker Therapeutics, Inc. | Tertiary amino lipidated cationic peptides for nucleic acid delivery |
| WO2022032058A1 (en) | 2020-08-07 | 2022-02-10 | Nutcracker Therapeutics, Inc. | Multicomponent delivery systems for polyanionic cargo compound delivery |
| NL2026825B1 (en) | 2020-08-07 | 2022-04-05 | Nutcracker Therapeutics Inc | Multicomponent delivery system for polyanionic cargo compound delivery |
| WO2022235923A2 (en) * | 2021-05-05 | 2022-11-10 | Arcturus Therapeutics, Inc. | Peptide-lipid conjugates |
| NL2029057B1 (en) | 2021-08-06 | 2023-02-21 | Nutcracker Therapeutics Inc | Compositions comprising hydroxyethyl-capped cationic peptoids |
| US20240307526A1 (en) | 2021-08-06 | 2024-09-19 | Nutcracker Therapeutics, Inc. | Compositions comprising hydroxyethyl-capped cationic peptoids |
| CN114778712B (en) * | 2022-03-21 | 2023-06-02 | 天津键凯科技有限公司 | Polyethylene glycol lipid and detection method for lipid nanoparticle content containing same |
| WO2024054617A1 (en) | 2022-09-09 | 2024-03-14 | Nutcracker Therapeutics, Inc. | 2-aminopropane-1,3-diol-capped cationic peptoids for nucleic acid delivery |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6287591B1 (en) | 1997-05-14 | 2001-09-11 | Inex Pharmaceuticals Corp. | Charged therapeutic agents encapsulated in lipid particles containing four lipid components |
| US6191115B1 (en) * | 1998-08-12 | 2001-02-20 | Abbott Laboratories | C-terminus modified heptapeptide LHRH analogs |
| WO2001016306A2 (en) | 1999-08-27 | 2001-03-08 | Chiron Corporation | Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
| US20030203865A1 (en) * | 2001-04-30 | 2003-10-30 | Pierrot Harvie | Lipid-comprising drug delivery complexes and methods for their production |
| CA2491164C (en) | 2002-06-28 | 2012-05-08 | Cory Giesbrecht | Method and apparatus for producing liposomes |
| AU2004257373B2 (en) | 2003-07-16 | 2011-03-24 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| WO2005060697A2 (en) * | 2003-12-19 | 2005-07-07 | Chiron Corporation | Cell transfecting formulations of small interfering rna, related compositions and methods of making and use |
| ITMI20061607A1 (en) * | 2006-08-09 | 2008-02-10 | Maria Vincenza Carriero | PEPTIDES WITH PHARMACOLOGICAL ACTIVITY |
| EP2155351B1 (en) | 2007-06-04 | 2021-02-17 | Pressure Biosciences, Inc. | Pressure-enhanced extraction and partitioning of molecules |
| HUE034483T2 (en) | 2008-04-15 | 2018-02-28 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
| CA3033577A1 (en) | 2008-11-10 | 2010-05-14 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| EP2350296A4 (en) * | 2008-11-17 | 2013-04-03 | Enzon Pharmaceuticals Inc | Branched cationic lipids for nucleic acids delivery system |
| EP2449114B9 (en) | 2009-07-01 | 2017-04-19 | Protiva Biotherapeutics Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| US20110053829A1 (en) * | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| EP2496700B1 (en) | 2009-11-04 | 2017-03-01 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
| DK2506857T3 (en) | 2009-12-01 | 2018-05-07 | Translate Bio Inc | SUPPLY OF MRNA FOR AMPLIFICATION OF PROTEINS AND ENZYMES IN HUMAN GENETIC DISEASES |
| WO2011153120A1 (en) | 2010-06-04 | 2011-12-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
| WO2012000104A1 (en) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| CN103328633B (en) | 2010-10-22 | 2018-07-10 | 成均馆大学校产学协力团 | Induce nucleic acid molecules of RNA interference and application thereof |
| EP2686342A2 (en) * | 2011-04-12 | 2014-01-22 | The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use |
| JP6184945B2 (en) | 2011-06-08 | 2017-08-23 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | Lipid nanoparticle compositions and methods for mRNA delivery |
| US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
| DK2830594T3 (en) | 2012-03-27 | 2018-08-13 | Sirna Therapeutics Inc | DIETHER-BASED BIOLOGICALLY DEGRADABLE CATIONIC LIPIDS FOR siRNA RELEASE |
| KR101480055B1 (en) | 2012-04-04 | 2015-01-09 | 주식회사 삼양바이오팜 | Method of Preparing Composition for Delivering an Anionic Drug |
| ES2864878T5 (en) | 2012-06-08 | 2024-10-23 | Translate Bio Inc | Pulmonary delivery of RNA to non-pulmonary target cells |
| WO2013192310A1 (en) | 2012-06-19 | 2013-12-27 | Massachusetts Institute Of Technology | Mass production and size control of nanoparticles through controlled microvortices |
| TW201726599A (en) | 2012-07-06 | 2017-08-01 | 協和醱酵麒麟有限公司 | Cationic lipid |
| US9687448B2 (en) | 2012-12-07 | 2017-06-27 | Alnylam Pharmaceuticals, Inc. | Nucleic acid lipid particle formulations |
| EP3750903A1 (en) | 2013-03-14 | 2020-12-16 | Translate Bio, Inc. | Ribonucleic acids with 4'-thio-modified nucleotides and related methods |
| MX2016002152A (en) | 2013-08-21 | 2017-01-05 | Curevac Ag | Method for increasing expression of rna-encoded proteins. |
| AU2015249553B2 (en) | 2014-04-23 | 2021-03-04 | Modernatx, Inc. | Nucleic acid vaccines |
| EP3155116A4 (en) | 2014-06-10 | 2017-12-27 | Massachusetts Institute Of Technology | Method for gene editing |
| ES2555160B1 (en) | 2014-06-24 | 2016-10-25 | Aptus Biotech, S.L. | Specific aptamers of TLR-4 and their uses |
| JP7105065B2 (en) | 2014-12-15 | 2022-07-22 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | Ligand-modified double-stranded nucleic acid |
| PT3324932T (en) | 2015-07-22 | 2021-04-06 | Nitto Denko Corp | Compositions and methods for nanoparticle lyophile forms |
| EP3364983A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Respiratory virus vaccines |
| ES2865030T3 (en) | 2015-12-13 | 2021-10-14 | Nitto Denko Corp | SiRNA structures for high activity and low nonspecificity |
| EP3519578B1 (en) * | 2016-10-03 | 2021-12-22 | Precision Nanosystems Inc | Compositions for transfecting resistant cell types |
| MX2019005470A (en) | 2016-11-10 | 2019-11-21 | Translate Bio Inc | Improved ice-based lipid nanoparticle formulation for delivery of mrna. |
| WO2018107061A1 (en) | 2016-12-09 | 2018-06-14 | Board Of Regents, The University Of Texas System | Hybrid exosomal-polymeric (hexpo) nano-platform for delivery of rnai therapeutics |
| US10844377B2 (en) | 2017-06-23 | 2020-11-24 | University Of Massachusetts | Two-tailed self-delivering siRNA |
| WO2020069442A1 (en) | 2018-09-28 | 2020-04-02 | Nutcracker Therapeutics, Inc. | Tertiary amino lipidated cationic peptides for nucleic acid delivery |
-
2019
- 2019-09-27 WO PCT/US2019/053655 patent/WO2020069442A1/en active Application Filing
- 2019-09-27 MX MX2021003420A patent/MX2021003420A/en unknown
- 2019-09-27 BR BR112021005815-0A patent/BR112021005815A2/en unknown
- 2019-09-27 MX MX2021003421A patent/MX2021003421A/en unknown
- 2019-09-27 JP JP2021517865A patent/JP7418419B2/en active Active
- 2019-09-27 IL IL281135A patent/IL281135B1/en unknown
- 2019-09-27 JP JP2021517802A patent/JP7430713B2/en active Active
- 2019-09-27 AU AU2019351268A patent/AU2019351268A1/en active Pending
- 2019-09-27 KR KR1020217012769A patent/KR20210068093A/en active Search and Examination
- 2019-09-27 SG SG11202102164PA patent/SG11202102164PA/en unknown
- 2019-09-27 AU AU2019347774A patent/AU2019347774A1/en active Pending
- 2019-09-27 KR KR1020217012768A patent/KR20210068092A/en unknown
- 2019-09-27 SG SG11202102163SA patent/SG11202102163SA/en unknown
- 2019-09-27 EP EP19866196.9A patent/EP3856757A4/en active Pending
- 2019-09-27 BR BR112021004929-0A patent/BR112021004929A2/en unknown
- 2019-09-27 US US17/279,460 patent/US20210322575A1/en active Pending
- 2019-09-27 CA CA3110914A patent/CA3110914A1/en active Pending
- 2019-09-27 CN CN201980062278.2A patent/CN112789031B/en active Active
- 2019-09-27 CA CA3111476A patent/CA3111476A1/en active Pending
- 2019-09-27 US US17/279,508 patent/US20210324002A1/en active Pending
- 2019-09-27 CN CN201980062070.0A patent/CN112805294A/en active Pending
- 2019-09-27 WO PCT/US2019/053661 patent/WO2020069445A1/en active Application Filing
- 2019-09-27 EP EP19864088.0A patent/EP3856146A4/en active Pending
-
2021
- 2021-02-26 ZA ZA2021/01376A patent/ZA202101376B/en unknown
- 2021-03-03 ZA ZA2021/01465A patent/ZA202101465B/en unknown
- 2021-03-19 IL IL281653A patent/IL281653A/en unknown
- 2021-06-14 US US17/347,498 patent/US11701434B2/en active Active
- 2021-06-14 US US17/347,539 patent/US11446394B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281653A (en) | Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery | |
| GB2600859B (en) | Improved lipid nanoparticles for delivery of nucleic acids | |
| IL290592A (en) | Ionizable cationic lipid for rna delivery | |
| EP3538515A4 (en) | Cationic lipids for nucleic acid delivery and preparation thereof | |
| IL286515A (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| IL283545B1 (en) | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| IL282995A (en) | Lipid nanoparticle formulations | |
| HK1244479A1 (en) | Ionizable cationic lipid for rna delivery | |
| EP3490562A4 (en) | Immolative cell-penetrating complexes for nucleic acid delivery | |
| EP3990441A4 (en) | Ionizable lipids for nucleic acid delivery | |
| EP3986866A4 (en) | Ionizable lipids for nucleic acid delivery | |
| LT3675826T (en) | Cationic lipid compositions for tissue-specific delivery | |
| IL290293A (en) | Lipidated cationic peptide-peg compositions for nucleic acid delivery | |
| IL304759A (en) | Lipids suitable for nucleic acid delivery | |
| EP3184506A4 (en) | Cationic lipid for nucleic acid delivery | |
| EP3836903C0 (en) | Lipid-based formulations containing salts for the delivery of rna |